FDA Elevates Vitruvias Thyroid Medication Recall to Class I Risk

The U.S. Food and Drug Administration (FDA) has escalated a voluntary recall of prescription thyroid medication to a Class I designation—the agency’s highest and most serious hazard classification. Issued after testing confirmed that select batches contained higher potency levels than stated on the label, the advisory warns that taking superpotent thyroid hormones could trigger severe medical complications, including life-threatening cardiac events.

(Jose Luis Magana, Copyright 2025 The Associated Press. All rights reserved)

Patients taking natural thyroid hormone replacement therapies are urged to inspect their prescription bottles immediately. The recalled product was distributed nationwide across the United States, prompting health authorities and the drug's manufacturer to issue direct guidance for consumers and healthcare providers.

Overview of the Nationwide Vitruvias Thyroid Recall

Thyroid medication bottle for hormone replacement. 

Source: Apollo Pharmacy

The action involves nearly 2,000 bottles of Thyroid Tablets, USP, manufactured and distributed by Vitruvias Therapeutics Inc., headquartered in Auburn, Alabama. The firm initiated a voluntary recall after quality control testing revealed that affected tablets contained excessive amounts of active ingredients, rendering them "superpotent."

Superpotency means patients consuming the standard prescribed dosage are unintentionally receiving elevated concentrations of active thyroid hormones. Because thyroid function regulates critical metabolic, cardiovascular, and neurological processes, accidental overdosage presents immediate health concerns.

Recalled Product Identification Details

Patients and caregivers should check their prescription containers against the specific identifying characteristics designated by the FDA:

• Product Name: Thyroid Tablets, USP (1/2 Grain / 30 mg)
• Quantity: 100-count bottles
• Total Quantity Affected: 1,955 bottles
• National Drug Code (NDC): 69680-166-00
• Lot Number: 504950
• Expiration Date: September 30, 2026
• Distribution Scope: Distributed nationwide across the United States

Why the FDA Assigned a Class I Classification

The FDA categorizes drug recalls into three risk-based levels. A Class I recall is reserved for situations in which exposure to or consumption of a violative product carries a reasonable probability of causing serious adverse health consequences or death.

The FDA's Center Classification Date for this action was designated as September 22.

Active Ingredients and Overexposure Risks

Each labeled 30 mg (1/2 Grain) Thyroid Tablet is formulated to contain two essential active thyroid hormones:

1. Levothyroxine (T4): 19 micrograms per tablet
2. Liothyronine (T3): 4.5 micrograms per tablet

When a batch is superpotent, the physical dose delivered exceeds these standardized ratios. Elevated systemic hormone levels can create a hyperthyroid-like state or acute thyroid toxicity.

Potential Health Risks and Symptoms of Thyroid Overdosage

Ingesting excess T3 and T4 hormones accelerates metabolic activity throughout the body, placing significant strain on vital organs. Individuals with pre-existing cardiovascular conditions, elderly patients, and those sensitive to hormonal fluctuation face the highest risk.

Potential adverse effects linked to superpotent thyroid hormone exposure include:

• Cardiovascular Distress: Rapid heart rate (tachycardia), irregular heart rhythms (arrhythmia), palpitations, chest tightness, or elevated blood pressure.
• Neurological & Psychological Symptoms: Severe anxiety, irritability, tremors, insomnia, and systemic restlessness.
• Metabolic Issues: Unexplained rapid weight loss, heat intolerance, excessive sweating, and extreme physical fatigue.
• Severe Complications: In high-risk groups, significant hormone overdoses can trigger acute cardiac events, heart failure, or severe thyrotoxicosis.

Important Guidance for Patients and Consumers

Health experts stress that patients holding affected bottles should take systematic steps to ensure their health and safety:

1. Verify Your Bottle: Inspect the NDC number, lot number (504950), and dosage details printed on your prescription bottle.
2. Stop Taking Affected Tablets: If your container matches the recalled lot, discontinue taking those specific tablets immediately.
3. Contact Your Prescriber: Reach out promptly to your physician or endocrinologist to secure an alternative, safe prescription so your thyroid management remains uninterrupted.
4. Consult Your Pharmacy: Local pharmacists can assist in verifying bottle details and facilitating replacement medications.
5. Report Adverse Events: Any health complications experienced while taking recalled tablets should be reported to a healthcare provider and submitted directly to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

Key Takeaways

• Recall Escalation: The FDA designated the nationwide voluntary recall of Vitruvias Thyroid Tablets as Class I, its most urgent risk level.
• Core Reason: Affected 30 mg (1/2 Grain) tablets were found to be superpotent, containing higher levels of active hormones (T3 and T4) than labeled.
• Targeted Lot: Applies to 1,955 100-count bottles under NDC 69680-166-00, Lot 504950, with an expiration date of Sept. 30, 2026.
• Action Steps: Patients possessing the affected lot should immediately halt usage, notify their doctor for a safe replacement, and contact their pharmacy.

Conclusion

The elevation of the Vitruvias Thyroid Tablets recall to Class I status highlights the serious clinical hazards associated with medication superpotency. Because precise thyroid hormone regulation is critical to cardiovascular and overall health, patients taking natural thyroid medications should inspect their prescription bottles without delay. If you hold a container from Lot 504950, cease taking the medication and consult your healthcare practitioner immediately to transition safely to an unaffected batch or alternative therapy.

The information I provided in this blog is for educational purposes only and does not substitute for professional medical advice. You should never use content in my writing as a substitute for direct medical advice from your doctor or another qualified clinician. Please consult a medical professional or healthcare provider if indicated for medical advice, diagnoses, or treatment. I am not liable for risks or issues associated with using or acting upon the information in this blog. Thank you.